Robin Tuytten

Robin is a globally respected leader in the field of mass spectrometry and women’s health. Prior to his appointment as CEO Robin had been leading the Metabolomic Diagnostics R&D programs. Robin is trained as an analytical chemist and holds a Ph.D. from the University of Antwerp where he developed methodologies for the mass spectrometric analyses of nucleosides and nucleotides. He joined Belgian biomarker company Pronota in 2006. Robin led Pronota’s Preeclampsia biomarker program until he joined Metabolomic Diagnostics. With more than 20 peer-reviewed scientific publications, co-inventorship on several technical and biomarker patent applications including protein biomarkers for PE, a solid track record in commercial biomarker development, and deep knowledge of the field of pregnancy diseases, Robin Tuytten is well-positioned to lead the company’s current and future product development efforts.